These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 38555682

  • 1. Risk-Adapted Strategy Combining Magnetic Resonance Imaging and Prostate-Specific Antigen Density to Individualize Biopsy Decision in Patients With PI-RADS 3 ``Gray Zone'' Lesions.
    Akpinar C, Oz DK, Oktar A, Suer E, Ozden E, Haliloglu N, Gulpinar O, Gokce MI, Gogus C, Baltaci S.
    Clin Genitourin Cancer; 2024 Jun; 22(3):102071. PubMed ID: 38555682
    [Abstract] [Full Text] [Related]

  • 2. Avoiding unnecessary biopsy: the combination of PRIMARY score with prostate-specific antigen density for prostate biopsy decision.
    Guo S, Zhang J, Wang Y, Jiao J, Li Z, Cui C, Chen J, Yang W, Ma S, Wu P, Jing Y, Wen W, Kang F, Wang J, Qin W.
    Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):288-293. PubMed ID: 38160227
    [Abstract] [Full Text] [Related]

  • 3. Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD).
    Falagario UG, Jambor I, Lantz A, Ettala O, Stabile A, Taimen P, Aronen HJ, Knaapila J, Perez IM, Gandaglia G, Fossati N, Martini A, Cucchiara V, Picker W, Haug E, Ratnani P, Haines K, Lewis S, Sujit N, Selvaggio O, Sanguedolce F, Macarini L, Cormio L, Nordström T, Tewari A, Briganti A, Boström PJ, Carrieri G.
    Eur Urol Oncol; 2021 Dec; 4(6):971-979. PubMed ID: 32972896
    [Abstract] [Full Text] [Related]

  • 4. Unlocking Precision Enhancing Prostate Cancer Detection and Reducing Unnecessary Biopsies with Combined Prostate-Specific Antigen Density and PI-RADS Score.
    Hamidi N, Uzel T, Demirci A, Basar H.
    J Coll Physicians Surg Pak; 2024 Oct; 34(10):1205-1210. PubMed ID: 39410690
    [Abstract] [Full Text] [Related]

  • 5. Predictors of prostate cancer detection in MRI PI-RADS 3 lesions - Reality of a tertiary center.
    Araújo D, Gromicho A, Dias J, Bastos S, Maciel RM, Sabença A, Xambre L.
    Arch Ital Urol Androl; 2023 Dec 20; 95(4):11830. PubMed ID: 38117217
    [Abstract] [Full Text] [Related]

  • 6. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
    Zhang Y, Zeng N, Zhang F, Huang Y, Tian Y.
    Int J Clin Oncol; 2020 Jan 20; 25(1):175-186. PubMed ID: 31473884
    [Abstract] [Full Text] [Related]

  • 7. Reduction of false positives using zone-specific prostate-specific antigen density for prostate MRI-based biopsy decision strategies.
    Hamm CA, Baumgärtner GL, Padhani AR, Froböse KP, Dräger F, Beetz NL, Savic LJ, Posch H, Lenk J, Schallenberg S, Maxeiner A, Cash H, Günzel K, Hamm B, Asbach P, Penzkofer T.
    Eur Radiol; 2024 Oct 20; 34(10):6229-6240. PubMed ID: 38538841
    [Abstract] [Full Text] [Related]

  • 8. Added Value of Prostate-specific Antigen Density in Selecting Prostate Biopsy Candidates Among Men with Elevated Prostate-specific Antigen and PI-RADS ≥3 Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: A Systematic Assessment by PI-RADS Score.
    Pellegrino F, Stabile A, Sorce G, Quarta L, Robesti D, Cannoletta D, Cirulli G, Barletta F, Scuderi S, Mazzone E, de Angelis M, Brembilla G, De Cobelli F, Salonia A, Montorsi F, Briganti A, Gandaglia G.
    Eur Urol Focus; 2024 Jul 20; 10(4):634-640. PubMed ID: 37865591
    [Abstract] [Full Text] [Related]

  • 9. Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
    Kaufmann B, Saba K, Schmidli TS, Stutz S, Bissig L, Britschgi AJ, Schaeren E, Gu A, Langenegger N, Sulser T, Eberli D, Keller EX, Hermanns T, Poyet C.
    Prostate; 2022 Feb 20; 82(3):388-396. PubMed ID: 34914121
    [Abstract] [Full Text] [Related]

  • 10. MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4∼10ng/mL: Biparametric versus multiparametric MRI.
    Han C, Liu S, Qin XB, Ma S, Zhu LN, Wang XY.
    Diagn Interv Imaging; 2020 Apr 20; 101(4):235-244. PubMed ID: 32063483
    [Abstract] [Full Text] [Related]

  • 11. The impact of prostate volume estimation on the risk-adapted biopsy decision based on prostate-specific antigen density and magnetic resonance imaging score.
    Baudewyns A, Guenzel K, Halinski A, Dariane C, Delavar G, Anract J, Barry Delongchamps N, Jabbour T, Bourgeno HA, Lefebvre Y, Ferriero M, Simone G, Fourcade A, Fournier G, Oderda M, Gontero P, Bernal-Gomez A, Mastrorosa A, Roche JB, Zahr RA, Ploussard G, Fiard G, Rysankova K, Bui AP, Taha F, Windisch O, Benamran D, Vlahopoulos L, Assenmacher G, Roumeguère T, Peltier A, Diamand R.
    World J Urol; 2024 May 15; 42(1):322. PubMed ID: 38747982
    [Abstract] [Full Text] [Related]

  • 12. Comparison of different thresholds of PSA density for risk stratification of PI-RADSv2.1 categories on prostate MRI.
    Girometti R, Giannarini G, Panebianco V, Maresca S, Cereser L, De Martino M, Pizzolitto S, Pecoraro M, Ficarra V, Zuiani C, Valotto C.
    Br J Radiol; 2022 Mar 01; 95(1131):20210886. PubMed ID: 34762506
    [Abstract] [Full Text] [Related]

  • 13. The Use of Multiparametric Magnetic Resonance Imaging for Follow-up of Patients Included in Active Surveillance Protocol. Can PSA Density Discriminate Patients at Different Risk of Reclassification?
    Roscigno M, Stabile A, Lughezzani G, Pepe P, Galosi AB, Naselli A, Naspro R, Nicolai M, La Croce G, Aljoulani M, Perugini G, Guazzoni G, Montorsi F, Balzarini L, Sironi S, Da Pozzo LF.
    Clin Genitourin Cancer; 2020 Dec 01; 18(6):e698-e704. PubMed ID: 32493676
    [Abstract] [Full Text] [Related]

  • 14. Avoiding Unnecessary Magnetic Resonance Imaging (MRI) and Biopsies: Negative and Positive Predictive Value of MRI According to Prostate-specific Antigen Density, 4Kscore and Risk Calculators.
    Falagario UG, Martini A, Wajswol E, Treacy PJ, Ratnani P, Jambor I, Anastos H, Lewis S, Haines K, Cormio L, Carrieri G, Rastinehad AR, Wiklund P, Tewari A.
    Eur Urol Oncol; 2020 Oct 01; 3(5):700-704. PubMed ID: 31548130
    [Abstract] [Full Text] [Related]

  • 15. Who with suspected prostate cancer can benefit from Proclarix after multiparametric magnetic resonance imaging?
    Morote J, Campistol M, Regis L, Celma A, de Torres I, Semidey ME, Roche S, Mast R, Santamaria A, Planas J, Trilla E.
    Int J Biol Markers; 2022 Jun 01; 37(2):218-223. PubMed ID: 35200058
    [Abstract] [Full Text] [Related]

  • 16. Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer.
    Deniffel D, Healy GM, Dong X, Ghai S, Salinas-Miranda E, Fleshner N, Hamilton R, Kulkarni G, Toi A, van der Kwast T, Zlotta A, Finelli A, Perlis N, Haider MA.
    Radiology; 2021 Aug 01; 300(2):369-379. PubMed ID: 34032510
    [Abstract] [Full Text] [Related]

  • 17. Combining clinical parameters and multiparametric magnetic resonance imaging to stratify biopsy-naïve men for an optimum diagnostic strategy with prostate-specific antigen 4 ng ml-1 to 10 ng ml-1.
    Zhang CC, Tu X, Lin TH, Cai DM, Yang L, Qiu S, Liu ZH, Yang L, Wei Q.
    Asian J Androl; 2023 Aug 01; 25(4):492-498. PubMed ID: 36571328
    [Abstract] [Full Text] [Related]

  • 18. Multivariable stratification of PI-RADS version 2.1 categories for the risk of false-positive target biopsy: Impact on prostate biopsy decisions.
    Girometti R, Giannarini G, De Martino M, Caregnato E, Cereser L, Soligo M, Rozze D, Pizzolitto S, Isola M, Zuiani C.
    Eur J Radiol; 2023 Aug 01; 165():110897. PubMed ID: 37300933
    [Abstract] [Full Text] [Related]

  • 19. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
    Stabile A, Dell'Oglio P, De Cobelli F, Esposito A, Gandaglia G, Fossati N, Brembilla G, Cristel G, Cardone G, Deho' F, Losa A, Suardi N, Gaboardi F, Del Maschio A, Montorsi F, Briganti A.
    Eur Urol Oncol; 2018 May 01; 1(1):29-36. PubMed ID: 31100225
    [Abstract] [Full Text] [Related]

  • 20. Molecular and diffusion features for identification of clinically significant prostate cancer in PI-RADS 3 lesions.
    Ajami T, Han S, Porto JG, Kimbel I, Szczotka Z, Guerard T, VanderVeer-Harris N, Ledesma BR, Acosta PC, Kryvenko ON, Parekh DJ, Stoyanova R, Reis IM, Punnen S.
    Urol Oncol; 2024 Nov 01; 42(11):370.e9-370.e14. PubMed ID: 38971674
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.